Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
NCI-CCC Tumor Board Question
•
AYA Tumor Board
•
Nationwide Children
What would be your therapeutic approach for an AYA patient with an unresectable thymic carcinoma?
Related Questions
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
How would you manage a young, HIV-negative patient with good performance status with primary refractory Burkitt Lymphoma involving the CNS and systemic disease?
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
Would you consider a cycle of EP in a patient with good risk stage IIIB seminoma on BEP but with bleomycin omitted for cycle 3?
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
What are the key local therapy considerations for patients with malignant pleural effusion, bulky pleural disease, lung metastases and chest wall/diaphragm primary in a patient with Rhabdomyosarcoma or Ewing Sarcoma?
Should improving imaging chest standards for staging impact the radiographic response criteria for lung metastases in Wilms?
